Cadrenal Therapeutics, Inc.

Stage 4 · Declining · week 47

As of Oct 22, 2026, Cadrenal Therapeutics is in Stage 4, the downtrend phase, now in week 47 (since Nov 18, 2025). It closed at $0.97, 93.1% below its 52-week high and below its 200-day average, which is falling.

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. More about the company

$0.97

-3.01% today

$3.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CVKD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 26w

S4 14w

S4 48w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 11w → S4 10w → S1 8w → S2 3w → S3 1w → S4 13w → S1 3w → S4 3w → S1 7w → S2 26w → S3 9w → S4 14w → S1 9w → S4 48w current

Total tracked: 165 weeks across 14 stage runs.

CVKD among Biotechnology523rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…523	CVKDCadrenal Therapeutics, Inc.	Stage 4 · wk 47	6	−26.5%

vs 52W High

-93.1%

$0.87 lo$14.14 hi

93.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 47

1w13w26w

Week 47, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-76.7%

200 DMA: $4.16 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.03x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-26.5%

-52.5%

-82.5%

YTD

-86.8%

-92.7%

Scan Membership

Breakout Watch

Latest: 2024-10-11

2 appearances in last 60 days. First seen: 2024-03-06.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 47 · Vol 0.03x

2026-10-21S4

Wk 47 · Vol 0.05x

2026-10-20S4

Wk 47 · Vol 0.08x

2026-10-19S4

Wk 46 · Vol 0.26x

2026-10-16S4

Wk 46 · Vol 0.30x

2026-10-15S4

Wk 46 · Vol 0.18x

2026-10-14S4

Wk 46 · Vol 0.60x

2026-10-13S4

Wk 46 · Vol 0.66x

2026-10-12S4

Wk 45 · Vol 0.20x

2026-10-09S4

Wk 45 · Vol 0.15x

2026-10-08S4

Wk 45 · Vol 0.56x

2026-10-07S4

Wk 45 · Vol 3.39x

Moving averages & range

50 DMA

$1.24

200 DMA

$4.16

52W High

$14.14

52W Low

$0.87

5D Low

$0.97

Resistance levels (recent highs)

20d High

$1.15

60d High

$2.09

120d High

$6.61

250d High

$14.14

Next resistance

+18.6%

to 20d High

ROE

-275.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.7

Cadrenal Therapeutics: quick answers

What stage is Cadrenal Therapeutics in?

As of Oct 22, 2026, Cadrenal Therapeutics (CVKD) is in Stage 4, the downtrend phase. It entered Stage 4 on Nov 18, 2025 and is in week 47. What the four stages mean

Is Cadrenal Therapeutics in an uptrend?

No. Cadrenal Therapeutics is in a Stage 4 downtrend. It trades 76.7% below its 200-day average, which is falling.

How far is Cadrenal Therapeutics from its 52-week high?

Cadrenal Therapeutics closed at $0.97 on Oct 22, 2026, 93.1% below its 52-week high of $14.14. Its 52-week low is $0.87.

How has Cadrenal Therapeutics performed over the past year?

As of Oct 22, 2026, Cadrenal Therapeutics is down 92.7% over the past year and down 86.8% so far in 2026.

Which sector and industry is Cadrenal Therapeutics in?

Cadrenal Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.